Full Press Release Details
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September:
Citi’s 2025 Biotech Back to School ConferenceDate:Wednesday, September 3rd, 2025Location:Boston, MAFormat:Fireside chat & 1x1 meetingsTime:11:15 a.m. ET
H.C. Wainwright 27thAnnual Global Investment ConferenceDate:Tuesday, September 9th, 2025Location:New York, NYFormat:Fireside chat & 1x1 meetingsTime:8:00 a.m. ET
Morgan Stanley 23rdAnnual Global Healthcare ConferenceDate:Wednesday, September 10th, 2025Location:New York, NYFormat:Fireside chat & 1x1 meetingsTime:8:30 a.m. ET
Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website atwww.arcusbio.com. Replays will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visitwww.arcusbio.com.
Investor InquiriesPia Eaves (Banerjee)VP of Investor Relations & Strategy(617) 459-2006peaves@arcusbio.com
Media InquiriesHolli KolkeyVP of Corporate Affairs(650) 922-1269hkolkey@arcusbio.com
Maryam BassiriAD, Corporate Communications(510) 406-8520mbassiri@arcusbio.com